stockrowClearmind Medicine Inc.
CMND Healthcare Biotechnology
- EPS
- +99.4%
- Free cash flow
- −77.9%
Quarter to July 2026, against a year earlier
Follow CMND
Alert me
Clearmind Medicine Inc. (CMND) Piotroski F-score
Piotroski F-score, annual
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|
How the score is made up
There are no annual figures to work it out from.
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| SXTP 60 Degrees Pharmaceuticals Inc. compare | 4 |
| KALA KALA BIO, Inc. compare | 3 |
| ADXN Addex Therapeutics Ltd. Sponsored ADR compare | 2 |
| AFMDQ Affimed N.V. compare | 1 |
| ERNA Ernexa Therapeutics Inc. compare | — |
| BCAB BioAtla, Inc. compare | — |
| JUNS Jupiter Neurosciences, Inc. compare | — |
| CMND Clearmind Medicine Inc. | — |
| MBIO Mustang Bio, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover